Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Source: onclive.com